Estimating the long-term effects of HPV vaccination in Germany

Vaccine

Volumn 31, Issue 19, 2013, Pages 2372-2380

  Horn, J ^a,b   Damm, O ^c   Kretzschmar, M E E ^d,e   Delere Y ^f   Wichmann, O ^f   Kaufmann, A M ^g   Garbe, E ^b   Kramer A ^c   Greiner, W ^c   Mikolajczyk, R T ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^c BIELEFELD UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f ROBERT KOCH INSTITUTE   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cervical cancer; HPV; Mathematical modelling; Vaccination effects

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CALIBRATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CHILD; CONDYLOMA ACUMINATUM; CROSS PROTECTION; FEMALE; GERMANY; HISTORY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SEXUAL TRANSMISSION; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; CHILD; CONDYLOMATA ACUMINATA; CROSS PROTECTION; FEMALE; FORECASTING; GERMANY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84876070548     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.006     Document Type: Article

References (61)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Munoz N., Bosch F.X., Castellsague X., Diaz M., de S.S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-285.
4. Dunne E.F., Markowitz L.E. Genital human papillomavirus infection. Clin Infect Dis 2006, 43(5):624-629.
5. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.(GEKID). 2012 cited; Available from: http://www.gekid.de/.
6. European Medicines Agency. Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use; 2006, http://venice.cineca.org/EPAR-gardasil.pdf.
7. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
8. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
9. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(7):926-935.
10. Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther 2010, 10(3):477-487.
11. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789.
12. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
13. Olsen J., Jepsen M.R. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010, 26(2):183-191.
14. Delere Y., Meyer C., Reiter S. Universal immunisation with human papillomavirus (HPV) vaccine among females aged 12-17 recommended in Germany. Euro Surveill 2007, 12(4):E070405.
15. Schwabe U., Paffrath D. Arzneiverordnungsreport 2009 2009, Springer, Heidelberg.
16. Seto K., Marra F., Raymakers A., Marra C.A. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012, 72(5):715-743.
17. Schneider A., Hammerschmidt T., Schwarz T.F., Rogoza R.M., Ferko N., Siebert U. Long-term public health impact of vaccination against cervical cancer in Germany. Geburtshilfe Frauenheilkd 2007, 67(8):850-858.
18. Hillemanns P., Petry K.U., Largeron N., McAllister R., Tolley K., Büsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Publ Health 2008, 17(2):77-86.
19. Sroczynski G, Schnell-Inderst P, Mühlberger N, et al., Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivität und Kosten-Effektivität des Einsatzes der HPV-DNA-Diagnostik imRahmen der Zervixkarzinomfrüherkennung in Deutschland.; 2010. Report No.: Bd. 98,.
20. Elbasha E.H., Galvani A.P. Vaccination against multiple HPV types. Math Biosci 2005, 197(1):88-117.
21. Choi Y.H., Jit M., Gay N., Cox A., Garnett G.P., Edmunds W.J. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28(24):4091-4102.
22. Zechmeister I., Blasio B.F., Garnett G., Neilson A.R., Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009, 27(37):5133-5141.
23. Tumorregister München. 2012 cited; Available from: http://www.tumorregister-muenchen.de/.
24. Mikolajczyk R.T., Horn J., Damm O., Kaufmann A.M., Kretzschmar M.E. Re: Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. J Natl Cancer Inst 2012, 104(2):163.
25. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(6):1911-1919.
26. Safaeian M., Porras C., Schiffman M., Rodriguez A.C., Wacholder S., Gonzalez P., et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102(21):1653-1662.
27. Antonsson A., Green A.C., Mallitt K.A., O'Rourke P.K., Pandeya N., Pawlita M., et al. Prevalence and stability of antibodies to 37 human papillomavirus types--a population-based longitudinal study. Virology 2010, 407(1):26-32.
28. Syrjanen S., Waterboer T., Sarkola M., Michael K., Rintala M., Syrjanen K., et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009, 90(Pt 6):1515-1526.
29. Kerek-Bodden H., Altenhofen L., Brenner G. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten 2009, Zentralinstitut für kassenärztliche Versorgung in der Bundesrepublik Deutschland, Berlin.
30. Jones B.A., Novis D.A. Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Arch Pathol Lab Med 1996, 120(6):523-531.
31. McCrory D.C., Matchar D.B., Bastian L., Datta S., Hasselblad V., Hickey J., et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ) 1999, (5):1-6.
32. Robert Koch-Institut Gesundheit in Deutschland 2006, Gesundheitsberichterstattung des Bundes. Robert Koch-Institut, Berlin.
33. Schwartz F.W. The effectiveness and ultilization of screening cytology for cervical cancer in the Federal Republic of Germany (author's transl.). Geburtshilfe Frauenheilkd 1981, 41(4):259-262.
34. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
35. Insinga R.P., Dasbach E.J., Elbasha E.H. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009, 9:119.
36. BQS Bundesgeschäftsstelle Qualitätssicherung. BQS-Bundesauswertung 2008. Gynäkologische Operationen. BQS, 2011. Available from: http://wwwbqs-outcomede/2008/ergebnisse/leistungsbereiche/gyn/buaw/uebasis.
37. Roteli-Martins C., Naud P., De B.P., Teixeira J., De C.N., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8(3).
38. Roggendorf H. Erste Erfahrungen zur Akzeptanz der HPV-Impfung. Durchimpfungsrate eines Jahrgangs in einer Großstadt 1 Jahr nach Impfempfehlung durch die STIKO. Monatsschr Kinderheilkd 2009, 102009:982-985.
39. Wild F. Impfung gegen humane Papillomviren (HPV). Eine Analyse der Verordnungsdaten Privatversicherter. WIP-Diskussionspapier 3/2011; 2011.
40. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
41. Kraut A.A., Schink T., Schulze-Rath R., Mikolajczyk R.T., Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010, 10:360.
42. Forhan S.E., Gottlieb S.L., Sternberg M.R., Xu F., Datta S.D., McQuillan G.M., et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics 2009, 124(6):1505-1512.
43. Iftner T., Eberle S., Iftner A., Holz B., Banik N., Quint W., et al. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol 2010, 82(11):1928-1939.
44. Klug S.J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry K.U., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007, 79(5):616-625.
45. Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000, 89(6):529-534.
46. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
47. Krebsregister Niedersachsen. 2012 cited. Available from: http://www.krebsregister-niedersachsen.de/.
48. Krebsregister Saarland. 2012 cited. Available from: http://www.krebsregister.saarland.de/.
49. Castellsague X., Diaz M., de Sanjose S., Munoz N., Herrero R., Franceschi S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006, 98(5):303-315.
50. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1157-1164.
51. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998.
52. Van de Velde N., Boily M.C., Drolet M., Franco E.L., Mayrand M.H., Kliewer E.V., et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104(22):1712-1723.
53. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
54. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 2008, 100(5):308-320.
55. Coupe V.M., de Melker H.E., Snijders P.J., Meijer C.J., Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine 2009, 27(37):5111-5119.
56. Krauss H., Bogdanski P., Szulinska M., Malewski M., Buraczynska-Andrzejewska B., Sosnowski P., et al. Sexual initiation of youths in selected European countries compared with their sexual and contraceptive knowledge. AAEM 2012, 19(3):587-592.
57. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(46):8443-8450.
58. Bogaards J.A., Kretzschmar M., Xiridou M., Meijer C.J., Berkhof J., Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS medicine 2011, 8(12):e1001147.
59. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
60. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
61. Brisson M., van de Velde N., Franco E.L., Drolet M., Boily M.C. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204(3):372-376.